CNCR | Loncar Cancer Immunotherapy ETF Overview

(Stock Exchange: NASDAQ)

Day's Range	15.40 - 15.72
52 Week Range	9.22 - 17.96
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	5,600
Average Volume	5,949
Shares Outstanding	825,150
Inception Date	2015-10-14

Assets	12,734,373
Asset Class	Equity
Expense Ratio	0.79
P/E Ratio	N/A
EPS	N/A
Dividend Yield	11.99%
Dividend Per Share	1.85
Dividend ExDate	N/A
Dividend PayDate	N/A

The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.

*Chart delayed

Watching at CNCR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CNCR Technicals page.